Merck & Company Inc's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Net-Income-From-Continuing-Operations" stands at 19.04 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Merck & Company Inc's third quarter result of 5.79 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 30.69 percent compared to it's second quarter result.
Also, Merck & Company Inc's third quarter result of 5.79 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 83.07 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Merck & Company Inc's third quarter result of 19.04 Billion USD for the item "Net Income From Continuing Operations" represents an increase of 15.99 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 56.57 percent compared to the value the year prior.
The 1 year change in percent is 56.57.
The 3 year change in percent is 24.20.
The 5 year change in percent is 65.05.
The 10 year change in percent is 76.25.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Income From Continuing Operations | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Income From Continuing Operations | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Income From Continuing Operations | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Income From Continuing Operations | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Income From Continuing Operations | 280,205,508,085.11 |